• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

增生性糖尿病视网膜病变、视网膜中央静脉阻塞和眼缺血综合征新生血管性青光眼的小梁切除术:手术结果和失败的预测因素。

Trabeculectomy for neovascular glaucoma in proliferative diabetic retinopathy, central retinal vein occlusion, and ocular ischemic syndrome: Surgical outcomes and prognostic factors for failure.

机构信息

VST Center for Glaucoma Care, L. V. Prasad Eye Institute, Hyderabad, Telangana, India.

Center for Biostatistcs and Epidemiology, L. V. Prasad Eye Institute, Hyderabad, Telangana, India.

出版信息

Indian J Ophthalmol. 2021 Nov;69(11):3341-3348. doi: 10.4103/ijo.IJO_1516_21.

DOI:10.4103/ijo.IJO_1516_21
PMID:34708802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8725114/
Abstract

PURPOSE

To evaluate the outcomes of trabeculectomy in the eyes with neovascular glaucoma (NVG), caused by proliferative diabetic retinopathy (PDR), central retinal vein occlusion (CRVO), and ocular ischemic syndrome (OIS).

METHODS

A retrospective review of NVG eyes that underwent trabeculectomy between 1991 and 2019. Complete success was defined as intraocular pressure (IOP) between 6 and 21 mmHg without antiglaucoma medications (AGM). The risk factors were analyzed by Cox's proportional hazard model.

RESULTS

The study included 100 eyes of 100 subjects with a mean age of 58 ± 9.8 years and a median follow-up of 1.27 years (interquartile range: 0.63, 2.27). The cause of NVG was PDR in 59 eyes (59%), CRVO in 25 eyes (25%), and OIS in 16 eyes (16%). Trabeculectomy with mitomycin-C was performed in 88 eyes and trabeculectomy in 12 eyes. The cumulative complete success probability of trabeculectomy in PDR was 50% (95% confidence interval [CI]: 38, 65) at 1 year, 8% (1, 46) at 3-5 years. In OIS, it was 64% (43, 96) from 1 to 5 years. In CRVO, it was 75% (59, 94) at 1 year, 45% (23, 86) from 2 to 5 years. The PDR was associated with a higher risk of surgical failure compared to OIS (P = 0.04) and CRVO (P = 0.004). Other significant risk factors were increasing age (P = 0.02), persistent neovascularization of iris (NVI) (P = 0.03), higher number of anti-vascular endothelial growth factor (VEGF) injections prior to trabeculectomy (P = 0.02), and delay in performing trabeculectomy (P = 0.02).

CONCLUSION

Compared to CRVO and OIS, the eyes with NVG secondary to PDR had poor success with trabeculectomy. Older age, persistent NVI, need for a higher number of anti-VEGF injections, and delayed surgery were associated with a higher risk for trabeculectomy failure.

摘要

目的

评估由增生性糖尿病视网膜病变(PDR)、视网膜中央静脉阻塞(CRVO)和眼缺血综合征(OIS)引起的新生血管性青光眼(NVG)患者行小梁切除术的结果。

方法

回顾性分析了 1991 年至 2019 年期间接受小梁切除术的 NVG 眼。完全成功定义为眼压(IOP)在 6 至 21mmHg 之间,无需抗青光眼药物(AGM)。通过 Cox 比例风险模型分析了危险因素。

结果

本研究共纳入 100 例 100 只眼,平均年龄 58±9.8 岁,中位随访时间为 1.27 年(四分位间距:0.63,2.27)。NVG 的病因是 PDR 59 只眼(59%),CRVO 25 只眼(25%),OIS 16 只眼(16%)。88 只眼行丝裂霉素 C 小梁切除术,12 只眼行小梁切除术。PDR 患者小梁切除术 1 年完全成功率为 50%(95%置信区间[CI]:38,65),3-5 年为 8%(1,46)。OIS 为 1 至 5 年为 64%(43,96)。CRVO 为 1 年为 75%(59,94),2 至 5 年为 45%(23,86)。与 OIS(P=0.04)和 CRVO(P=0.004)相比,PDR 患者手术失败的风险更高。其他显著的危险因素包括年龄增长(P=0.02)、虹膜新生血管持续存在(NVI)(P=0.03)、小梁切除术前抗血管内皮生长因子(VEGF)注射次数增加(P=0.02)和小梁切除术延迟(P=0.02)。

结论

与 CRVO 和 OIS 相比,继发于 PDR 的 NVG 患者小梁切除术成功率较低。年龄较大、持续的 NVI、需要更多的抗 VEGF 注射以及手术延迟与小梁切除术失败的风险增加相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e751/8725114/068517c19eba/IJO-69-3341-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e751/8725114/068517c19eba/IJO-69-3341-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e751/8725114/068517c19eba/IJO-69-3341-g001.jpg

相似文献

1
Trabeculectomy for neovascular glaucoma in proliferative diabetic retinopathy, central retinal vein occlusion, and ocular ischemic syndrome: Surgical outcomes and prognostic factors for failure.增生性糖尿病视网膜病变、视网膜中央静脉阻塞和眼缺血综合征新生血管性青光眼的小梁切除术:手术结果和失败的预测因素。
Indian J Ophthalmol. 2021 Nov;69(11):3341-3348. doi: 10.4103/ijo.IJO_1516_21.
2
A review of neovascular glaucoma. Etiopathogenesis and treatment.新生血管性青光眼的综述。病因发病机制与治疗。
Rom J Ophthalmol. 2021 Oct-Dec;65(4):315-329. doi: 10.22336/rjo.2021.66.
3
Full preoperative panretinal photocoagulation improves the outcome of trabeculectomy with mitomycin C for neovascular glaucoma.术前全视网膜光凝可改善丝裂霉素C小梁切除术治疗新生血管性青光眼的效果。
Eur J Ophthalmol. 2008 Sep-Oct;18(5):758-64. doi: 10.1177/112067210801800516.
4
Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma.玻璃体内注射贝伐单抗与滤过手术治疗新生血管性青光眼的手术结果
Adv Ther. 2008 May;25(5):438-43. doi: 10.1007/s12325-008-0047-5.
5
Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term.抗血管内皮生长因子(VEGF)治疗是短期内新生血管性青光眼治疗的关键策略。
BMC Ophthalmol. 2016 Aug 30;16(1):150. doi: 10.1186/s12886-016-0327-9.
6
Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure.丝裂霉素C辅助小梁切除术治疗新生血管性青光眼:手术失败的预后因素
Am J Ophthalmol. 2009 May;147(5):912-8, 918.e1. doi: 10.1016/j.ajo.2008.11.015. Epub 2009 Feb 5.
7
Neovascular glaucoma after central retinal vein occlusion in pre-existing glaucoma.已有青光眼患者发生视网膜中央静脉阻塞后的新生血管性青光眼。
BMC Ophthalmol. 2014 Oct 5;14:119. doi: 10.1186/1471-2415-14-119.
8
Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma.全视网膜光凝联合冷冻视网膜固定术或玻璃体腔内贝伐单抗治疗新生血管性青光眼。
Graefes Arch Clin Exp Ophthalmol. 2013 May;251(5):1355-60. doi: 10.1007/s00417-012-2236-9. Epub 2012 Dec 19.
9
The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma.不同剂量前房内注射贝伐单抗对新生血管性青光眼小梁切除术手术效果的影响
Eur J Ophthalmol. 2009 May-Jun;19(3):435-41. doi: 10.1177/112067210901900318.
10
Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma.玻璃体切割联合全视网膜光凝及小梁切除术成功治疗新生血管性青光眼
Graefes Arch Clin Exp Ophthalmol. 2006 Dec;244(12):1627-32. doi: 10.1007/s00417-006-0321-7.

引用本文的文献

1
Early Intrableb Features on Anterior Segment Swept-Source Optical Coherence Tomography Predict Surgical Success After Trabeculectomy in Uveitic and Neovascular Glaucoma.眼前节扫频源光学相干断层扫描的早期小梁内特征可预测葡萄膜炎性和新生血管性青光眼小梁切除术后的手术成功率
J Clin Med. 2025 Aug 5;14(15):5499. doi: 10.3390/jcm14155499.
2
Neovascular Glaucoma With Persistent Epithelial Defect: Pathophysiology and Surgical Solutions.伴有持续性上皮缺损的新生血管性青光眼:病理生理学与手术解决方案
Cureus. 2025 May 17;17(5):e84275. doi: 10.7759/cureus.84275. eCollection 2025 May.
3
Surgical Outcomes of Mitomycin-C Augmented Trabeculectomy in Neovascular Glaucoma and Prognostic Factors for Surgical Failure in Thailand.

本文引用的文献

1
Outcomes of neovascular glaucoma in eyes presenting with moderate to good visual potential.具有中等到良好视力潜力的患眼的新生血管性青光眼的结局。
Int Ophthalmol. 2021 Jul;41(7):2359-2368. doi: 10.1007/s10792-021-01789-y. Epub 2021 Mar 21.
2
Neovascular glaucoma - A review.新生血管性青光眼——综述。
Indian J Ophthalmol. 2021 Mar;69(3):525-534. doi: 10.4103/ijo.IJO_1591_20.
3
Clinical Analysis of 42 Cases of Ocular Ischemic Syndrome.42例眼缺血综合征的临床分析
泰国新生血管性青光眼患者丝裂霉素C辅助小梁切除术的手术结果及手术失败的预后因素
Clin Ophthalmol. 2024 Nov 1;18:3111-3123. doi: 10.2147/OPTH.S485331. eCollection 2024.
4
Demographic, Socioeconomic, and Clinical Factors Associated with Severe Vision Loss in Patients with Neovascular Glaucoma.与新生血管性青光眼患者严重视力丧失相关的人口统计学、社会经济和临床因素
Clin Ophthalmol. 2024 Jul 19;18:2137-2145. doi: 10.2147/OPTH.S452884. eCollection 2024.
5
Factors Affecting the Results of Ahmed Glaucoma Valve Implantation in Diabetic Neovascular Glaucoma With or Without Previous Pars Plana Vitrectomy.影响有无既往玻璃体切割术的糖尿病性新生血管性青光眼患者行艾哈迈德青光眼引流阀植入术效果的因素
Beyoglu Eye J. 2024 Jun 1;9(2):76-85. doi: 10.14744/bej.2024.64497. eCollection 2024.
6
The mechanism and therapeutic strategies for neovascular glaucoma secondary to diabetic retinopathy.糖尿病视网膜病变继发新生血管性青光眼的发病机制与治疗策略。
Front Endocrinol (Lausanne). 2023 Jan 23;14:1102361. doi: 10.3389/fendo.2023.1102361. eCollection 2023.
7
Downregulation of angiogenic factors in aqueous humor associated with less intraoperative bleeding in PDR patients with NVG receiving conbercept: a randomized controlled trial.与接受康柏西普的 NVG 合并 PDR 患者术中出血减少相关的房水中血管生成因子下调:一项随机对照试验。
BMC Ophthalmol. 2022 May 18;22(1):224. doi: 10.1186/s12886-022-02451-6.
J Ophthalmol. 2018 Mar 11;2018:2606147. doi: 10.1155/2018/2606147. eCollection 2018.
4
Ahmed Valves vs Trabeculectomy Combined with Pans Plana Vitrectomy for Neovascular Glaucoma with Vitreous Hemorrhage.艾哈迈德引流阀与小梁切除术联合玻璃体全切除术治疗合并玻璃体积血的新生血管性青光眼的比较
Eur J Ophthalmol. 2017 Nov 8;27(6):774-780. doi: 10.5301/ejo.5000973.
5
Neovascular glaucoma: a review.新生血管性青光眼:综述
Int J Retina Vitreous. 2016 Nov 14;2:26. doi: 10.1186/s40942-016-0051-x. eCollection 2016.
6
Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications.玻璃体内注射雷珠单抗联合小梁切除术与艾哈迈德人工房水引流阀植入术治疗新生血管性青光眼的疗效及并发症评估
BMC Ophthalmol. 2016 May 26;16:65. doi: 10.1186/s12886-016-0248-7.
7
Long-Term Outcomes and Prognostic Factors of Trabeculectomy following Intraocular Bevacizumab Injection for Neovascular Glaucoma.玻璃体内注射贝伐单抗治疗新生血管性青光眼后小梁切除术的长期疗效及预后因素
PLoS One. 2015 Aug 14;10(8):e0135766. doi: 10.1371/journal.pone.0135766. eCollection 2015.
8
Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis.前房积血是新生血管性青光眼行小梁切除术失败的危险因素:回顾性分析。
BMC Ophthalmol. 2014 Apr 26;14:55. doi: 10.1186/1471-2415-14-55.
9
Recent advances in the management of neovascular glaucoma.新生血管性青光眼治疗的最新进展
Semin Ophthalmol. 2013 May;28(3):165-72. doi: 10.3109/08820538.2012.730103.
10
Intracameral ranibizumab and subsequent mitomycin C augmented trabeculectomy in neovascular glaucoma.前房内雷珠单抗联合后续丝裂霉素 C 增强的小梁切除术治疗新生血管性青光眼。
J Glaucoma. 2014 Sep;23(7):437-40. doi: 10.1097/IJG.0b013e3182946398.